A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
An open-label, dose escalation and maximum tolerated dose (MTD) and/or recommended phase II
dose (RPTD) study of fruquintinib combined with paclitaxel in patients with advanced gastric
cancer who did not respond to first-line standard chemotherapy.